此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002

2026年7月23日 更新者:Hangzhou MacroLink Biopharmaceutical LLC

A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics, and Preliminary Efficacy of MC002 in Participants With Locally Advanced/Metastatic Solid Tumors

The goal of this clinical trial is to learn if ADC drug MC002 works to treat locally advanced/metastatic solid tumors in adults. It will also learn about the safety of MC002. The main questions it aims to answer are:

Does participants tolerate the drug MC002 ? What medical problems do participants have when treating with MC002? Does participants benefit from the MC002

.

Participants will:

Intravenous infusion MC002 every 3 weeks in clinical Visit the clinic once every 3 weeks for checkups and tests Keep a diary of their symptoms

研究概览

地位

尚未招聘

研究类型

介入性

注册 (估计的)

143

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • 18 years of age and over, male or female, able to understand and willing to sign the Informed Consent Form (ICF).
  • Life expectancy of 3 month or greater
  • participants with histologically or cytologically confirmed recurrent or metastatic unresectable advanced solid tumors who experience disease progression after receiving systemic standard therapy, or have no standard therapy.
  • At least one measurable lesion as assessed by RECIST 1.1
  • Adequate organ functions.
  • ECOG Performance Status (PS) of 0-1

Exclusion Criteria:

  • Pregnant or nursing females.Participants who have received chemotherapy, investigational therapy, immunotherapy, or any other antitumor active drugs within 4 weeks or 5 half-lives (whichever is shorter) before the first dose.
  • Known hypersensitivity to either the drug substances or inactive ingredient
  • Participants who have undergone a bone marrow transplantation, solid organ transplantation, stem cell transplant.
  • Participants with QTc >470 msec.
  • Use of ≥10 mg of prednisone or equivalent dose of steroids per day within 3 months of administration (inhaled, intranasal, intraocular, topical and intraarticular joint injections of corticosteroids are allowed).Participants with a history of HCV infection who have not completed curative anti HCV treatment and whose HCV load is above the limit of quantification. Concurrent HCV treatment is not allowed in the trial.Live viral vaccine therapies within 4 weeks prior to the first dose of study drug.
  • Participants who have received treatment with any herbal or alternative therapies within 7 days prior to the first dose of the study drug.
  • Male and female participants of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:dose escalation
MC002 dose escalation
MC002 is a recombinant antibody-drug conjugate targeting the oncofetal antigen.A complete treatment cycle is defined as 21 calendar days. MC002 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To assess the Number of patients with Adverse Events (AE)
大体时间:From enrollmenFrom enrollment until 28 days after last study drug t to the safety follow up
Any medical event in a participant which may or may not have a causal relationship with this treatment.
From enrollmenFrom enrollment until 28 days after last study drug t to the safety follow up
Determination of MTD or RP2D
大体时间:From enrollment until 28 days after last study drug
Maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of MC002
From enrollment until 28 days after last study drug

次要结果测量

结果测量
措施说明
大体时间
Maximum concentration (Cmax)
大体时间:From enrollment until 28 days after last study drug
The concentration of MC002 (conjugated ADC), total mAb, and free payload (Cmax will be derived).
From enrollment until 28 days after last study drug
ADA
大体时间:From enrollment until 28 after last study drug
Incidence, onset time, and titer of ADAs against MC002
From enrollment until 28 after last study drug
The time taken to reach the maximum concentration (Tmax)
大体时间:From enrollment until 28 days after last study drug
The concentration of MC002 (conjugated ADC), total mAb, and free payload (Tmax will be derived).
From enrollment until 28 days after last study drug
Area Under Curve (AUC)
大体时间:From enrollment until 28 days after last study drug
PK endpoint
From enrollment until 28 days after last study drug
Half life (T1/2)
大体时间:From enrollment until 28 days after last study drug
Half life (T1/2)
From enrollment until 28 days after last study drug
Trough concentration (Cmin)
大体时间:From enrollment until 28 days after last study drug
The concentration of MC002 (conjugated ADC), total mAb, and free payload (Cmin will be derived)
From enrollment until 28 days after last study drug

其他结果措施

结果测量
措施说明
大体时间
Overall response rate (ORR)
大体时间:From enrollment until 28 days after last study drug.
the proportion/percentage of participants with best overall response of CR or PR。
From enrollment until 28 days after last study drug.
progression-free survival (PFS)
大体时间:From enrollment until 28 days after last study drug.
assessed per RECISTv1.1
From enrollment until 28 days after last study drug.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2027年12月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2026年7月10日

首先提交符合 QC 标准的

2026年7月20日

首次发布 (实际的)

2026年7月24日

研究记录更新

最后更新发布 (实际的)

2026年7月27日

上次提交的符合 QC 标准的更新

2026年7月23日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • MC002 FIH Study
  • Sponsor (其他赠款/资助编号:Sponsor)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅